Bullous Eosinophilic Cellulitis in a Child Treated with Dapsone

Moon, Sung-Hyuk; Shin, Min Kyung

doi:10.1111/j.1525-1470.2012.01841.x

Cited by 14 publications

(8 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of dapsone in the treatment regimen of eosinophilic cellulitis has been reported quite often . After failure of systemic steroids, 100 mg dapsone was initiated daily, showing a remission of lesions within a short period of 2 weeks.…”

Section: Resultsmentioning

confidence: 99%

“…The use of dapsone in the treatment regimen of eosinophilic cellulitis has been reported quite often. 4,[27][28][29] After failure of systemic steroids, 100 mg dapsone was initiated daily, showing a remission of lesions within a short period of 2 weeks. Afterwards the dose of dapsone was reduced to 50 mg daily for 6 weeks and later to 50 mg thrice a week.…”

Section: Dapsonementioning

confidence: 99%

See 1 more Smart Citation

Treatment of eosinophilic cellulitis (Wells syndrome) – a systematic review

Räßler

Lukács

Elsner

2016

Acad Dermatol Venereol

View full text Add to dashboard Cite

Eosinophilic cellulitis (Wells syndrome) is a rare inflammatory skin disease defined by erythematous, tender, sometimes urticarial plaques, possibly with vesicles and bullae, and granulomatous eosinophilic infiltrates in the dermis. Usually the disease has a benign course with spontaneous remission within a few weeks. Nevertheless, recurrences are quite frequent and may occur for several years. The objective of this study was to review the so far reported treatment options for Wells syndrome in a systematic manner. This systematic review is based on a search on Medline, Embase and Cochrane Central Register for English and German articles from 1970 to 2015. Advices on the treatment of Wells syndrome are limited predominately to case reports or to small case series. There are no randomized controlled trials, and control groups are missing. A variety of treatment options for Wells syndrome were reported including topical and systemic corticosteroids, antihistamines, cyclosporine, dapsone, azathioprine, griseofulvin, doxycycline, minocycline, antimalarial medications, oral tacrolimus/topical tacrolimus, sulfasalazine, interferon alpha and gamma, TNF alpha inhibitors, colchicine and PUVA therapy. As well-designed, randomized controlled trials are missing, no guidelines for the treatment of this disease can be given. Due to the small number of patients and the frequent misdiagnosis of this clinical entity, the aim of this systematic overview is to call attention to this rare condition and to help clinicians to diagnose and treat Wells syndrome effectively. Due to the good prognosis and tendency to resolve, systemic treatment should be limited to cases resistant to local therapy or with widespread lesions.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Dapsonementioning

confidence: 99%

Treatment of eosinophilic cellulitis (Wells syndrome) – a systematic review

Räßler

Lukács

Elsner

2016

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Blood eosinophilia could be found in more than 50% of the cases (29 of 45 cases; 64%); in these patients, the level of eosinophils fluctuates with the course of the disease, returning to reference range on clinical remission. In only seven cases bullous lesions were present (7,(12)(13)(14)(15)(16). The extremities are most frequently affected, but truncal involvement is also observed.…”

Section: Discussionmentioning

confidence: 99%

Wells� syndrome in childhood: two case reports with review of the literature

Farina¹

2014

CDERM

View full text Add to dashboard Cite

SummaryWells' syndrome, or eosinophilic cellulitis, is a rare disorder manifesting with acute erythematous and edematous plaques which resolve completely. Bullous lesions are uncommon, especially in childhood. We present two pediatric cases of bullous Wells' syndrome, one 3-year-old boy with atypical cutaneous manifestations and one 6-month-old girl with typical skin lesions. No trigger factors could be identified in both cases. Treatment with topical and systemic steroids was performed. Both patients had no recurrences after two years. Fortyfive pediatric cases of Wells' syndrome have been reported in the literature with an average age of onset of five years. In only seven cases bullous lesions were present. In about half of the patients a precipitating factor has been identified, including infections, arthropod bites, drug administration and hematologic disorders.

show abstract

“…Eosinophilic cellulitis is an uncommon, inflammatory and recurrent disorder which is more frequently observed in adults than in children [3, 4]. Despite its etiology remaining unknown, hypersensitive responses to different stimuli such as insect bites, fungal and viral infections, medications (including TNF inhibitors), vaccinations, eczema and hematologic malignant disorders, among others [3, 4], have been proposed.…”

Section: Discussionmentioning

confidence: 99%

“…Despite its etiology remaining unknown, hypersensitive responses to different stimuli such as insect bites, fungal and viral infections, medications (including TNF inhibitors), vaccinations, eczema and hematologic malignant disorders, among others [3, 4], have been proposed.…”

Section: Discussionmentioning

confidence: 99%

Wells’ Syndrome Successfully Treated with Colchicine

et al. 2017

View full text Add to dashboard Cite

Eosinophilic cellulitis is an uncommon, inflammatory and chronic disorder of unknown etiology. Corticosteroids are currently considered as the first-line treatment but they are not without significant disadvantages such as contraindications in steroid-resistant cases and patients with frequent recurrences. We report a patient suffering from Wells’ syndrome with a 24-year history of symptomatic and generalized skin lesions. After consultation in our department, treatment with colchicine 1 mg/day was prescribed resulting in large clinical improvement. No side effects have been recorded. To our knowledge, this is an original disease approach. Although small, our clinical experience supports the inclusion of colchicine in the drug armamentarium when treating patients suffering from Wells’ syndrome. Indeed, its excellent safety profile makes it very attractive for patients with frequent recurrent episodes who need secure options for the medium- and long-term disease control.

show abstract

Bullous Eosinophilic Cellulitis in a Child Treated with Dapsone

Cited by 14 publications

References 4 publications

Treatment of eosinophilic cellulitis (Wells syndrome) – a systematic review

Treatment of eosinophilic cellulitis (Wells syndrome) – a systematic review

Wells� syndrome in childhood: two case reports with review of the literature

Wells’ Syndrome Successfully Treated with Colchicine

Contact Info

Product

Resources

About